B. Braun Receives FDA Approval of Daytona Beach Pharmaceutical Manufacturing Site
- B.Braun Medical, Inc.
BETHLEHEM, Pa., Jan. 28, 2022 /PRNewswire/ — B. Braun Medical Inc. (B. Braun), a leader in infusion therapy and pain management, today announced that the company has received final approval by the U.S. Food & Drug Administration (FDA) for its new pharmaceutical manufacturing plant in Daytona Beach, FL. The site will produce 0.9% Sodium Chloride for Injection available in B. Braun’s Excel® Plus IV Bags in 1,000 mL and 500 mL sizes. Consistent with B. Braun’s decades-long commitment to protect patients from exposure to harmful chemicals, the Excel Plus IV bags are not made with PVC, DEHP or natural rubber latex. Read more…
Related Reading
Blog / Diagnostics / Digital Health / Regulatory Affairs / Standards
Honoring Janet E. Trunzo: A Legacy That Shaped Modern Medtech Regulation
January 29, 2026
After 30 years at AdvaMed, Janet E. Trunzo, Senior Advisor to the President and Senior Executive Vice President of Technology and Regulatory Affairs, will retire on January 31, 2026. Her tenure has fundamentally shaped how medical devices are regulated in the United States and globally, establishing frameworks and standards that continue to govern the field today.
Blog / Regulatory Affairs
Strengthen Your IDE Strategy at AdvaMed’s IDE Submissions Workshop
January 27, 2026
Gain in-depth IDE submission training, meaningful face time with FDA and regulatory leaders, and RAPS accreditation credits at AdvaMed’s IDE Submissions Workshop.
Resource / AdvaMed Advancements / Emerging Policy Response Resources / Global & Trade / Tariffs
AdvaMed® Advancements: Q4 2025 Report
January 27, 2026
AdvaMed® Advancements: Q4 2025 Report highlights how unified industry advocacy responded to policy disruption, trade uncertainty, and federal action impacting medtech.
News / Coverage & Payment / Diagnostics / Regulatory Affairs
AdvaMed Names Brian J. Blaser, QuidelOrtho President and CEO, Chair of AdvaMedDx Board of Directors
January 21, 2026
WASHINGTON, D.C.—AdvaMed, the Medtech Association, today announced that Brian Blaser, president and CEO of QuidelOrtho, will serve as the next chair of the AdvaMedDx Division Board of Directors, succeeding Thierry Bernard, CEO of QIAGEN. AdvaMedDx represents more than 70 manufacturers of the innovative in vitro diagnostic (IVD) tests critical to patient care.
News / Artificial Intelligence (AI) / Coverage & Payment / Diagnostics / Digital Health / Government & Legislative Affairs / Medical Imaging / Regulatory Affairs
Medical Imaging Division Announces Rich Fabian as New Board Chair
January 16, 2026
WASHINGTON, D.C.—AdvaMed, the Medtech Association, today announced that Rich Fabian, president and CEO of FUJIFILM Sonosite, will serve as the chair of the Medical Imaging division’s board of directors. He will succeed David Pacitti, CEO of Avanos Medical and former president and head of the Americas at Siemens Healthineers, the inaugural division board chair.
News / Artificial Intelligence (AI) / Coverage & Payment / Diagnostics / Digital Health / Government & Legislative Affairs / Orthopedic / Regulatory Affairs
Robert Cohen of Stryker Named Chair of AdvaMed’s Digital Health Tech Division Board of Directors
January 5, 2026
WASHINGTON, D.C.—AdvaMed, the Medtech Association, today announced that Robert Cohen, vice president, innovation and technology, orthopaedic group at Stryker, will be the next chair of the AdvaMed Digital Health Tech Board of Directors. He succeeds Dr. Taha Kass-Hout, global chief science and technology officer at GE HealthCare, who served as the inaugural chair of the board overseeing the then-newly created division.
News / Artificial Intelligence (AI) / Coverage & Payment / Diagnostics / Digital Health / Government & Legislative Affairs / Medical Imaging / Orthopedic / Regulatory Affairs / Small Business
Mick Farrell, Chairman and CEO of Resmed, Named Chair of AdvaMed Board of Directors
December 11, 2025
WASHINGTON, D.C.—AdvaMed, the Medtech Association, today announced Michael “Mick” Farrell, chairman and CEO of Resmed Inc. (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing, and care delivered in the home, will be the next chair of the AdvaMed Board of Directors. Farrell will serve a two-year term beginning in January 2026.
Event / Regulatory Affairs
Medical Device Submissions Series: Investigational Device Exemption (IDE) Workshop
8:30 am – 5:15 pm ET
February 25, 2026
Our in-depth device submissions workshops will provide real-world case studies, tips and best practices directly from FDA and industry experts.